Nyxoah S.A.
General ticker "NYXH" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $211.0M (TTM average)
Nyxoah S.A. does not follow the US Stock Market performance with the rate: -30.9%.
Estimated limits based on current volatility of 3.0%: low 2.89$, high 3.07$
Factors to consider:
- Total employees count: 106 as of 2021
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.39$, 6.91$]
- 2026-12-31 to 2027-12-31 estimated range: [2.29$, 6.54$]
Financial Metrics affecting the NYXH estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 17.24 > -0.60
- Positive: Interest expense per share per price, % of 1.11 <= 3.31
- Negative: negative Net income
- Positive: Inventory ratio change, % of -23.12 <= -0.75
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 1.51
Short-term NYXH quotes
Long-term NYXH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €4.35MM | €4.52MM | €10.02MM |
| Operating Expenses | €49.45MM | €63.33MM | €92.96MM |
| Operating Income | €-45.10MM | €-58.81MM | €-82.94MM |
| Non-Operating Income | €0.45MM | €2.38MM | €-6.13MM |
| Interest Expense | €1.21MM | €1.90MM | €1.69MM |
| R&D Expense | €27.66MM | €34.33MM | €42.82MM |
| Income(Loss) | €-44.66MM | €-56.43MM | €-89.08MM |
| Taxes | €0.00MM | €0.00MM | €1.01MM |
| Net Income(Loss)* | €-43.21MM | €-59.24MM | €-90.12MM |
| Stockholders Equity | €98.02MM | €113.25MM | €49.11MM |
| Inventory | €3.31MM | €4.72MM | €4.66MM |
| Assets | €124.16MM | €158.41MM | €118.43MM |
| Operating Cash Flow | €-44.78MM | €-49.23MM | €-67.50MM |
| Capital expenditure | €10.96MM | €6.07MM | €0.80MM |
| Investing Cash Flow | €32.01MM | €-16.32MM | €26.17MM |
| Financing Cash Flow | €16.86MM | €77.44MM | €38.79MM |
| Earnings Per Share** | €-1.55 | €-1.81 | €-2.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.